Cargando…

In vivo visualization of PARP inhibitor pharmacodynamics

BACKGROUND: [(18)F]FluorThanatrace ([(18)F]FTT) is a radiolabeled poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that enables noninvasive quantification of PARP with potential to serve as a biomarker for patient selection for PARPi therapy. Here we report for the first time to our...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonald, Elizabeth S., Pantel, Austin R., Shah, Payal D., Farwell, Michael D., Clark, Amy S., Doot, Robert K., Pryma, Daniel A., Carlin, Sean D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Clinical Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119179/ https://www.ncbi.nlm.nih.gov/pubmed/33884961 http://dx.doi.org/10.1172/jci.insight.146592

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer
por: Sunkara, Tejasvi, et al.
Publicado: (2022)

Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo
por: Shao, Zhengping, et al.
Publicado: (2020)

Principles of Tracer Kinetic Analysis in Oncology, Part II: Examples and Future Directions
por: Pantel, Austin R., et al.
Publicado: (2022)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Perfusion-only imaging in pregnant women: A comparative reader study with implications for practice patterns
por: Schroeder, Jennifer A., et al.
Publicado: (2022)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Predicting PARP inhibitor sensitivity and resistance
por: Bebb, D. Gwyn, et al.
Publicado: (2012)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia
por: Herriott, Ashleigh, et al.
Publicado: (2015)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

3′-5′ Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo
por: Toledano, Elie, et al.
Publicado: (2012)

Successes and Challenges of PARP Inhibitors in Cancer Therapy
por: Ricks, Tiffany K., et al.
Publicado: (2015)

PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites
por: Lin, Xiaohui, et al.
Publicado: (2022)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Clinical PARP inhibitors allosterically induce PARP2 retention on DNA
por: Langelier, Marie-France, et al.
Publicado: (2023)

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?
por: Heym, Peter-Paul, et al.
Publicado: (2012)

Characterization of the interactions of PARP-1 with UV-damaged DNA in vivo and in vitro
por: Purohit, Nupur K., et al.
Publicado: (2016)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

A phase I study of pazopanib in combination with escalating doses of (131)I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine
por: Chow, Laura Q., et al.
Publicado: (2017)

Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics
por: Budic, Ivana, et al.
Publicado: (2022)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Prokhorova, Evgeniia, et al.
Publicado: (2021)

A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism
por: Choi, Young Hee, et al.
Publicado: (2021)

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets
por: Shah, Girish M., et al.
Publicado: (2013)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

In vitro analysis of PARP inhibitor nanoformulations
por: Baldwin, Paige, et al.
Publicado: (2018)

Checkpoint and PARP inhibitors, for whom and when
por: Lee, Jung-Min, et al.
Publicado: (2017)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP and PARG inhibitors in cancer treatment
por: Slade, Dea
Publicado: (2020)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vkl6poi8f8pq4bhuer2gdq2qlq